Samuel E. Broder

Q: What Schools Are Affiliated With Samuel E. Broder

Samuel E. Broder is affiliated with the following schools: Boston University, University of Michigan

Samuel E. Broder's AcademicInfluence.com Rankings

Samuel E. Broder

Philosophy

#4674

World Rank

#7284

Historical Rank

Logic

#2082

World Rank

#2992

Historical Rank

philosophy Degrees

Samuel E. Broder

Biology

#6168

World Rank

#8825

Historical Rank

Computational Biology

#100

World Rank

#100

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Samuel E. Broder's Degrees

Bachelors Chemistry Rutgers University

Why Is Samuel E. Broder Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Samuel E. Broder's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The Sequence of the Human Genome (2001) (6572)
The Genome Sequence of the Malaria Mosquito Anopheles gambiae (2002) (2020)
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. (1985) (1657)
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. (1981) (1266)
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. (1986) (1219)
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. (1986) (891)
ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX (1986) (733)
Molecular targets for AIDS therapy. (1990) (648)
Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia. (1974) (633)
Ovarian cancer: screening, treatment, and followup. (1995) (579)
Designing CD4 immunoadhesins for AIDS therapy (1989) (466)
PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT) (1988) (464)
The Sézary syndrome: a malignant proliferation of helper T cells. (1976) (442)
Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. (1988) (439)
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. (2010) (434)
Strategies for antiviral therapy in AIDS (1987) (426)
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. (1987) (415)
Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. (1983) (404)
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. (1989) (395)
Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection (1988) (391)
Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells. (1975) (387)
Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases (1987) (375)
Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. (1984) (360)
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. (1989) (329)
A pathogenic retrovirus (HTLV-III) linked to AIDS. (1984) (328)
RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS-ASSOCIATED NEUROLOGICAL DISEASE TO 3'-AZIDO-3'-DEOXYTHYMIDINE (1987) (321)
Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido- 2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine (1989) (283)
Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. (1990) (277)
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents. (1987) (275)
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. (1986) (238)
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. (1993) (230)
The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. (1987) (223)
Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. (1978) (222)
Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associa (1986) (219)
Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. A progress report. (1987) (218)
Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. (1989) (215)
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. (1986) (213)
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex (1990) (208)
Textbook of AIDS Medicine (1994) (205)
Association of the human type C retrovirus with a subset of adult T-cell cancers. (1983) (197)
Treatment of HIV-associated Kaposi's sarcoma with paclitaxel (1995) (190)
EFFECTS OF SURAMIN ON HTLV-III/LAV INFECTION PRESENTING AS KAPOSI'S SARCOMA OR AIDS-RELATED COMPLEX: CLINICAL PHARMACOLOGY AND SUPPRESSION OF VIRUS REPLICATION IN VIVO (1985) (188)
Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. (1993) (185)
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. (1987) (177)
The suppressor-cell network in cancer (first of two parts). (1978) (176)
The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. (1988) (174)
X-linked hypogammaglobulinemia and isolated growth hormone deficiency. (1980) (170)
Human T-cell leukemia-lymphoma virus (HTLV) is in T but not B lymphocytes from a patient with cutaneous T-cell lymphoma. (1982) (162)
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. (1990) (159)
Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxynucleotide. (1989) (156)
Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. (1998) (155)
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. (1988) (153)
Polyclonal B-cell activators in the study of the regulation of immunoglobulin synthesis in the human system. (1982) (152)
Characterization of a suppressor-cell leukemia. Evidence for the requirement of an interaction of two T cells in the development of human suppressor effector cells. (1978) (152)
Fc-Receptors on Human T Lymphocytes I. Transition of Tγ to Tµ Cells (1978) (150)
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. (1979) (148)
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. (1984) (147)
Clinical Pharmacokinetics of Suramin in Patients With HTLV‐III/LAV Infection (1986) (144)
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. (1991) (140)
Implications of the human genome for understanding human biology and medicine. (2001) (136)
Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. (1991) (133)
Suppressor cells in the regulation of the immune response. (1977) (132)
Pharmacokinetics of 2′, 3′‐dideoxyadenosine and 2′, 3′‐dideoxyinosine in patients with severe human immunodeficiency virus infection (1990) (131)
Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine. (1986) (125)
Rapid Communication—The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses—Report of the 1991 Bethesda Workshop (1992) (124)
Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. (2006) (123)
Estrogen Receptor Genotypes and Haplotypes Associated with Breast Cancer Risk (2004) (117)
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. (1993) (117)
Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. (1988) (114)
Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogues. (1987) (111)
Studies on the mechanism of human immunodeficiency virus reverse transcriptase. Steady-state kinetics, processivity, and polynucleotide inhibition. (1988) (110)
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS‐related complex (1989) (110)
Molecular foundations of cancer: New targets for intervention (1995) (110)
From the National Institutes of Health. (1992) (105)
Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′‐dideoxycytidine (ddc) (1989) (104)
The pharmacokinetics of zidovudine administered by continuous infusion in children. (1989) (101)
2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). (1987) (100)
Pharmacokinetics of 2‘,3’‐Dideoxycytidine in Patients with AIDS and Related Disorders (1988) (99)
Sequencing the entire genomes of free-living organisms: the foundation of pharmacology in the new millennium. (2000) (98)
The role of suppressor cells in the pathogenesis of common variable hypogammaglobulinemia and the immunodeficiency associated with myeloma. (1976) (95)
Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection. (1990) (95)
(±)-Dioxolane-T ((±)-1-[(2β,4β)-2-(hydroxymethyl)-4-dioxolanyl]thymine): a new 2',3'-dideoxynucleoside prototype with in vitro activity against HIV (1989) (94)
Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV) (1986) (93)
Developmental therapeutics and the acquired immunodeficiency syndrome. (1987) (90)
Suppressor cells in neoplastic disease. (1978) (89)
Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor (1983) (89)
T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners. (1989) (89)
Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. (1991) (86)
Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease (1988) (86)
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. (2009) (84)
Metabolic heterogeneity of eosinophils from normal and hypereosinophilic patients. (1981) (84)
Broad spectrum antiretroviral activity of 2',3'-dideoxynucleosides. (1987) (84)
Infection of monocytes by human immunodeficiency virus type 1 blocked by inhibitors of CD4-gp120 binding, even in the presence of enhancing antibodies (1990) (81)
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. (1987) (80)
Aurintricarboxylic acid and Evans Blue represent two different classes of anionic compounds which selectively inhibit the cytopathogenicity of human T-cell lymphotropic virus type III/lymphadenopathy-associated virus. (1986) (79)
Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus (1983) (77)
Disorders of B cells and helper T cells in the pathogenesis of the immunoglobulin deficiency of patients with ataxia telangiectasia. (1983) (76)
Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. (1992) (75)
2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. (1987) (71)
The suppressor-cell network in cancer (second of two parts). (1978) (71)
Targeted therapy of human immunodeficiency virus‐related disease (1991) (69)
Reversal of brain metabolic abnormalities following treatment of AIDS dementia complex with 3'-azido-2',3'-dideoxythymidine (AZT, zidovudine): a PET-FDG study. (1989) (68)
Defect in IgA secretion and in IgA specific suppressor cells in patients with selective IgA deficiency. (1976) (68)
Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro (1990) (68)
Phosphoroselenoate oligodeoxynucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity. (1989) (67)
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. (1991) (65)
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. (1987) (65)
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature (2008) (64)
AIDS, modern concepts and therapeutic challenges (1987) (63)
1-(2,3-Anhydro-beta-D-lyxofuranosyl)cytosine derivatives as potential inhibitors of the human immunodeficiency virus. (1988) (63)
A MALIGNANT PROLIFERATION OF HELPER T CELLS (1976) (60)
Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. (1993) (59)
Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. (1986) (59)
Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. (1988) (58)
Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I. (1986) (58)
Pharmacological inhibition of in vitro infectivity of human T lymphotropic virus type I. (1987) (58)
Phosphorothioate oligodeoxynucleotides are potent sequence nonspecific inhibitors of de novo infection by HIV. (1989) (57)
Synthesis of phosphorothioate analogues of oligodeoxyribonucleotides and their antiviral activity against human immunodeficiency virus (HIV). (1988) (57)
Pilot study of the immunologic effects of recombinant human growth hormone and recombinant insulin‐like growth factor in HIV‐infected patients (1998) (56)
Implications of new proteomics strategies for biology and medicine. (2004) (56)
Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI). (1990) (56)
Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection. (1989) (54)
Evolution of a lymphoma with helper T cell characteristics in Sézary syndrome. (1978) (54)
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxycytidine. A potent inhibitor of reverse transcriptase. (1989) (54)
Pharmacokinetics of 2',3' ‐dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications (1991) (53)
Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. (1990) (53)
Synthesis and anti-HIV activity of isonucleosides. (1992) (52)
Antiretroviral Therapy in AIDS (1990) (51)
Cytogenetic studies in human T-cell lymphoma virus (HTLV)-positive leukemia-lymphoma in the United States. (1985) (51)
Functional properties of antigen-specific T cells infected by human T-cell leukemia-lymphoma virus (HTLV-I). (1984) (50)
Serum immunoglobulin E levels in patients with neoplastic disease. (1974) (50)
Transformation and cytopathogenic effect in an immune human T-cell clone infected by HTLV-I. (1984) (50)
Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. (1992) (49)
Corticosteroid-responsive intestinal lymphangiectasia secondary to an inflammatory process. (1979) (48)
Overview of the preclinical development of an antiretroviral drug, 2',3'-dideoxyinosine. (1990) (47)
Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. (1991) (47)
2'-Fluoro-2',3'-dideoxyarabinosyladenine: a metabolically stable analogue of the antiretroviral agent 2',3'-dideoxyadenosine. (1990) (46)
Polyclonal Activation of Human B Lymphocytes by Nocardia Water Soluble Mitogen (NWSM) (1979) (46)
Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages (1992) (46)
Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. (1995) (45)
In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors (1990) (45)
Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. (1995) (45)
Fc-IgM and Fc-IgG receptors on human circulating B lymphocytes. (1978) (44)
Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. (1992) (43)
Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage. (1994) (43)
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. (1976) (43)
Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. (1993) (43)
Initial Clinical Experience with Dideoxynucleosides as Single Agents and in Combination Therapy (1990) (42)
New directions in molecular medicine. (1994) (42)
Interleukin-10 suppresses human immunodeficiency virus-1 replication in vitro in cells of the monocyte/macrophage lineage (1994) (41)
Human T-cell leukemia virus: its discovery and role in leukemogenesis and immunosuppression. (1984) (40)
Anti-retroviral therapy of AIDS and related disorders: general principles and specific development of dideoxynucleosides. (1989) (40)
Activation of leukemic pro-suppressor cells to become suppressor-effector cells. Influence of cooperating normal T cells. (1981) (39)
Participation of suppressor T cells in the immunosuppressive activity of a heteroantiserum to human Ia-like antigens (p23,30) (1980) (38)
Suppressor T cells in the pathogenesis of hypogammaglobulinemia associated with a thymoma. (1975) (38)
In Vitro Functions of Human T Cells Expressing Fc‐IgG or Fc‐IgM Receptors (1981) (37)
Differences in the interaction of HIV-1 and HIV-2 with CD4. (1990) (37)
Alterations in cytotoxic and helper T cell function after infection of T cell clones with human T cell leukemia virus, type I. (1986) (36)
A pilot study of 2′,3′‐dideoxyinosine for the treatment of chronic hepatitis B (1992) (35)
Inhibition of infectivity and replication of HIV-2 and SIV in helper T-cells by 2',3'-dideoxynucleosides in vitro. (1988) (35)
Whole genomes: the foundation of new biology and medicine. (2000) (33)
Suramin and function of the adrenal cortex. (1986) (32)
Suppression of retroviral propagation and disease by suramin in murine systems. (1985) (31)
Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus. (1990) (31)
PROTEIN‐LOSING ENTEROPATHIES IN MALIGNANCY (1974) (30)
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. (1993) (29)
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma (1981) (29)
Human T-cell leukemia viruses (HTLV): a unique family of pathogenic retroviruses. (1985) (29)
Sequence analysis of the human genome: implications for the understanding of nervous system function and disease. (2001) (28)
The metabolism of IgE in patients with immunodeficiency states and neoplastic conditions. (1977) (28)
Cures for the Third World's problems (2002) (28)
Perspectives on Cancer in Japan and the United States' (1993) (28)
Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection. (1989) (27)
A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. (2009) (27)
Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. (1990) (27)
Regression of a T-cell lymphoma after administration of antithymocyte globulin. (1978) (26)
Neoplasms of immunoregulatory cells. (1979) (26)
In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells. (1991) (26)
Molecular foundations of oncology (1991) (25)
1-(3-cyano-2,3-dideoxy-beta-D-erythro-pentofuranosyl)thymine (cyanothymidine): synthesis and antiviral evaluation against human immunodeficiency virus. (1989) (24)
Twenty-Five Years of Translational Medicine in Antiretroviral Therapy: Promises to Keep (2010) (23)
Alpha, beta- and beta, gamma-methylene 5'-phosphonate derivatives of 3'-azido-2',3'-dideoxythymidine-5'-triphosphate. Correlation between affinity for reverse transcriptase, susceptibility to hydrolysis by phosphodiesterases and anti-retrovirus activity. (1988) (23)
Challenges in the therapy of HIV infection. (1993) (22)
Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents. (1990) (22)
Acid-Stable 2′-Fluoro Purine Dideoxynucleosides as Active Agents Against HIV. (1990) (21)
2',3'-Dideoxyadenosine is selectively toxic for TdT-positive cells. (1988) (21)
Current concepts in immunoregulatory T-cell neoplasms. (1979) (21)
Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design. (2006) (19)
Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection. (1995) (19)
Configuration and expression of the T cell receptor beta chain gene in human T-lymphotrophic virus I-infected cells (1986) (18)
Clinical applications of 3′‐azido‐2′,3′‐ dideoxythymidine (AZT) and related dideoxynucleosides (1990) (18)
The Bethesda system for reporting cervical/vaginal cytologic diagnosis–report of the 1991 bethesda workshop (1992) (17)
Inhibitory activity of antibodies to human Ia-like determinants: comparison of intact and pepsin-digested antibodies. (1983) (17)
Pharmacological inhibition of infectivity of HTLV-III in vitro. (1985) (15)
High molecular weight antigens present on human T cells. (1980) (15)
The occurrence of opportunistic non-Hodgkin's lymphomas in the setting of infection with the human immunodeficiency virus. (1991) (14)
Pathogenic human retroviruses. (1988) (14)
Fraud in breast-cancer trials. (1994) (14)
The human costs of cancer and the response of the national cancer program (1991) (14)
CUTANEOUS T-CELL LYMPHOMAS (1976) (14)
Chemotherapy for lymphoma in a patient with common variable immunodeficiency: case report, literature review, and recommendations for chemotherapy in immunodeficient patients. (1982) (13)
Dideoxycytidine: current clinical experience and future prospects. A summary. (1990) (13)
Challenges in the therapy of HIV infection. (1993) (13)
Infection of human T lymphotropic virus-I-specific immune T cell clones by human T lymphotropic virus-I. (1986) (13)
FOLLOW-UP OF NEUROPATHY FROM 2',3'-DIDEOXYCYTYTIDINE (1988) (13)
Progress in drug therapies for HIV infection. (1988) (12)
Characteristics of Multiple Myeloma as an Immunodeficiency Disease (1980) (12)
Perspective: The expanding challenge of HIV‐associated malignancies (1992) (11)
Dideoxycytidine (ddC): a potent antiretroviral agent for human immunodeficiency virus infection. An introduction. (1990) (11)
lmmunologic Enhancement of Tumor Xenografts by Pepsin-Degraded Immunoglobulin (1968) (11)
FUSIDIC ACID, HIV, AND HOST CELL TOXICITY (1988) (10)
The pathogenesis of AIDS lymphomas: a foundation for addressing the challenges of therapy and prevention. (1992) (10)
Neoplasms of immunoregulatory T cells in clinical investigation. (1980) (10)
Characterization of lymphoblast Fc receptor expression in acute lymphoblastic leukemia. (1979) (10)
Microbial disease in humans: A genomic perspective. (2001) (10)
Controlled trial methodology and progress in treatment of the acquired immunodeficiency syndrome (AIDS). A quid pro quo. (1989) (9)
Application of the Human Genome to Obstetrics and Gynecology (2002) (9)
The immunology of HIV infection: implications for therapy. (1992) (9)
Reactivity of lupus erythematosus antibodies with leukemic helper T cells. (1978) (9)
Fc receptors on human T lymphocytes. V: Effects of colchicine and cytochalasin B on Fc receptor expression. (1980) (9)
FURTHER CHARACTERIZATION OF NEOPLASTIC HELPER T CELLS FROM PATIENTS WITH THE SÉZARY SYNDROME (1977) (9)
Immunoregulatory functions of cultured human T lymphocytes. (1980) (9)
Acquired immune deficiency syndrome (AIDS) and Kaposi's sarcoma: clinical relationship between immunodeficiency disease and cancer. (1985) (9)
Principles of Antiretroviral Therapy for AIDS and Related Diseases (1988) (9)
AIDS therapies. (1988) (9)
The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnosis—Report of the 1991 Bethesda Workshop (1992) (8)
Antiviral therapy against HIV infection. (1990) (8)
Therapy of AIDS and AIDS-associated neoplasms. (1992) (8)
IMMUNE T CELLS REACTIVE AGAINST HUMAN T-CELL LEUKAEMIA/LYMPHOMA VIRUS (1984) (8)
(.+-.)-Dioxolane-T: A New 2′,3′-Dideoxynucleoside Prototype with in vitro Activity Against HIV. (1990) (8)
Immunologic issues in anti-retroviral therapy. (1990) (8)
Anabolism and Mechanism of Action of Ro24‐5098, an Isomer of 2′,3′‐Dideoxyadenosine (ddA) with Anti‐HIV Activity (1990) (7)
Fc IgM receptors on human lymphoblastoid B cell lines (1978) (7)
Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells. (1978) (7)
Progress in the development of antiviral therapy for HTLV-III-associated diseases. (1987) (7)
Strategies for the combination therapy of HIV infection. (1990) (7)
Effect of a recombinant CD4-IgG on in vitro T helper cell function: data from a phase I/II study of patients with AIDS. (1993) (7)
Editorial: HIV-associated non-Hodgkin's lymphomas (1991) (7)
Trends in program project grant funding at the National Cancer Institute. (1993) (6)
Microbial Disease in Humans: A Genomic Perspective (2012) (6)
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. (1981) (6)
Chapter 26. Therapeutic Strategies in the Treatment of AIDS (1988) (6)
Unusual clonal evolution in a case of chronic myelogenous leukemia. (1976) (6)
Human T-Cell Retrovirus and Adult T-Cell Lymphoma and Leukemia: Possible Factors on Viral Incidence (1983) (6)
Antiretroviral chemotherapy against human immunodeficiency virus (hiv) infection: perspective for therapy of hepatitis B virus infection. (1989) (6)
AIDS and related disorders. (1988) (6)
Synthesis and Evaluation of 2′,3′-Dideoxy-9-Deazaadenoslne and Some Related Derivatives (1989) (5)
Implications of the discovery of HTLV-III for the treatment of AIDS. (1985) (5)
The molecular pathology of lymphomas. (1986) (5)
NIH conference. Antiretroviral therapy in AIDS. (1990) (5)
Cigarette advertising and corporate responsibility. (1992) (5)
HIV-associated non-Hodgkin's lymphomas. (1991) (4)
Factors in the development of AIDS-related lymphomas. (1992) (4)
The challenge of cancer research (1993) (4)
T cell proliferation and ablation. A biologic spectrum of abnormalities induced by the human T cell lymphotropic virus group. (1986) (4)
Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development. (1992) (4)
Trial of Antisense RNA Inhibition of HIV Replication and Gene Expression (1991) (4)
Progress against cancer (2005) (4)
Regulation of the humoral immune response: from immunoglobulin genes to regulatory T cell networks. (1983) (4)
Perspectives in CancerResearch Acquired Immunodeficiency Syndrome and Non-Hodgkin's Lymphomas (1991) (3)
DYSFUNCTION OF SUPPRESSOR MECHANISMS ASSOCIATED WITH IMMUNODEFICIENCY AND AUTOIMMUNITY (1977) (3)
Normal and malignant T cells in the regulation of inflammation and immunity. (1980) (3)
Method, compositions and kits to increase the oral bioavailability of pharmaceutical agents. (1996) (3)
Multiplex genotyping and gene expression assays for colorectal cancer treatment selection markers (2005) (3)
Therapeutic horizons--the human genome. (2002) (3)
Cellular regulation of immune function. (1980) (3)
AIDS: a general overview. (1985) (2)
Workshop on Taxol and Taxus. Introduction. (1993) (2)
17 – Toward the Rational Design of Antiretroviral Therapy for Human Immunodeficiency Virus (HIV) Infection (1991) (2)
Targeted therapy against human immunodeficiency virus (1990) (2)
Abnormalities of immunoregulatory cells in immunodeficiency disease and cancer. (1981) (2)
CHAPTER 5 – T-T INTERACTIONS IN THE GENERATION OF HUMAN SUPPRESSOR EFFECTOR CELLS IN VITRO (1979) (2)
Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro. (1984) (2)
Potential Anti-AIDS Drugs. 2′,3′-Dideoxycytidine Analogues. (1987) (2)
Disorders of Suppressor T Cells in Immunodeficiency and Malignancy (1980) (2)
Strategies for experimental therapy of the retrovirus which causes aids (1987) (1)
Genomics, science and medicine: the future is now (2001) (1)
Immunologic enhancement of tumor xenografts by pepsin-degraded immunoglobulin. (1969) (1)
SUPPRESSION OF IMMUNOGLOBULIN SYNTHESIS IN VITRO BY PURIFIED ANTIBODY TO IgD (1976) (1)
The interrelationship between acquired immunodeficiency syndrome and cancer research. (1990) (1)
Regulation of synthesis of immunoglobulins (1976) (1)
Progress in targeted therapy against human immunodeficiency virus [corrected]. (1990) (1)
Oncology and hematology. (1994) (1)
IMST-07. LOCAL REGULATED IL-12 EXPRESSION AS AN IMMUNOTHERAPY FOR THE TREATMENT OF PONTINE GLIOMA (2016) (1)
Fc-Receptors on Human T Lymphocytes (1978) (1)
The human genome and comparative genomics: understanding human evolution, biology, and medicine. (2003) (1)
Protein-losing enteropathy in malignancy. (1977) (1)
Human T-cell leukemia/lymphoma viruses (HTLV): a unique family of pathogenic retroviruses. (1985) (1)
T cell disorders in primary immunodeficiency diseases (1978) (1)
Toward targeted therapy for HIV infection (1990) (1)
Targeted therapy againts human immunodeficiency virus (1989) (0)
Anti-retroviral compound (1988) (0)
1-(3-Cyano-2,3-dideoxy-β-D-erythro-pentofuranosyl)thymine (Cyanothymidine) (I): Synthesis and Antiviral Evaluation Against Human Immunodeficiency Virus. (1989) (0)
Travelling the genomic road (2001) (0)
InVitro Inhibition oftheInfectivity andReplication ofHuman Immunodeficiency Virus Type1byCombination ofAntiretroviral (1990) (0)
Generation of Antigen-specific Helper-inducer Clones . (2003) (0)
Abstract P5-02-01: Regulated intratumoral expression of IL-12 in combination with cytotoxic agents as a strategy for the treatment of metastatic breast cancer (2013) (0)
Therapy of AIDS and AIDS-related tumors. (1991) (0)
T Cell Proliferation and Ablation (1986) (0)
Cyclobut-A (I) and Cyclobut-G (II): Broad-Spectrum Antiviral Agents with Potential Utility for the Therapy of AIDS. (1990) (0)
Agents for the treatment of AIDS caused by viruses of infectious dementia (1989) (0)
Progress and challenges in the global effort against cancer (1991) (0)
Strategies for the future chemotherapy of human immunodeficiency virus (HIV). (1987) (0)
-6-fluoro-9-(2,3-dideoxy-b-d-glycero-pentofuranosyl)-9h-purines and their use asantiviral agents (1991) (0)
Compositions for oral administration of taxanes and to their use (1998) (0)
Progress in the Molecular Medicine of Cancer (1995) (0)
Abnormal Immunoregulation in Pediatric Cancer and Immunodeficiency (1981) (0)
Ic issues in anti-retrovirai lherapy (1990) (0)
Abstract P4-07-05: Correlation of a Proliferation Index Combined with Progesterone Receptor to Oncotype DX® in Early Stage ER-Positive Breast Cancer (2010) (0)
Winning the war on cancer. (1997) (0)
Clinical Features of Human T-Cell Leukemia/Lymphoma Virus (HTLV) Associated T-Cell Neoplasms (1984) (0)
Disorders of suppressor mediators associated with immunodeficiency and autoimmunity (1976) (0)
Contents, Vol. 56, 1676 (1976) (0)
F(ab') 2 -like immunoglobulin fragments in urines from patients with systemic lupus erythematosus. (1972) (0)
Index autorum ad Vol. 56, 1976 (1976) (0)
Impaired in vitro immunoglobulin synthesis by peripheral blood lymphocytes from patients with myeloma: possible role of suppressor cells (1975) (0)
Regulatory t-cell abnormalities in spqc 11 plasmacytoma- -bearing mice. Abstr. (1981) (0)
H-107 Speaking in honor of Ray Schinazi: Thirty years of anti-retroviral therapy for patients with AIDS (2017) (0)
Book ReviewDiagnosis and Treatment of Immunodeficiency Diseases (1981) (0)
Neoplastic Disease Levels in Patients with Serum Immunoglobulin E and (2006) (0)
A method, compositions, and set in enhancing the oral bioavailability of pharmaceutical agents (1996) (0)
Development of Opportunistic Non-Hodgkin’s Lymphomas in Severely Immunosuppressed HIV-Infected Patients Receiving Long-Term Antiretroviral Therapy (1992) (0)
Therapy of acquired immunodeficiency syndrome. (1987) (0)
ULMWH (ultra-low-molecular weight heparin) for the treatment of asthma (1996) (0)
146 Therapy Against HIV-1/AIDS: Past, Present, Future (2012) (0)
Composite and component expression score correlations in ER-positive breast cancer. (2010) (0)
Letter from Samuel Broder to Mary Lasker (1990) (0)
Macrophages and HIV: Perspectives of antiviral chemotherapy (1989) (0)
Fifth International Conference on AIDS : the Scientific and Social Challenge; plenary session transcript; state-of-the-art (1989) (0)
Nucleosides OD process for its preparation (1988) (0)
Samuel Broder, MD, reflects on the 30th anniversary of the National Cancer Act. Interviewed by Brian Vastag. (2001) (0)
Comparative measures of proliferation using Ki-67 Labeling Index and a 14-gene prognostic expression signature in breast cancer (2008) (0)
Perspectivesin CancerResearch Acquired Immunodeficiency Syndrome and Non-Hodgkin's Lymphomas (2006) (0)
AIDS: Progress and Challenges in Therapy (1992) (0)
Abstract B116: Molecular profiling of breast cancer cell lines using signatures reported in prognostic and predictive patient studies (2009) (0)
ULMWH (ultralow molecular weight heparin) to treat asthma. (1996) (0)
Science Translational Medicine Podcast: 7 July 2010 (2010) (0)
Index rerum ad Vol. 56, 1976 (1976) (0)
Advances and challenges in cancer research (1989) (0)
Clinical Applications of 3′-Azido-2′,3′-dideoxythymidine (AZT) and Related Dideoxynucleosides (1991) (0)
Synthesis and Anti‐HIV Activity of Isonucleosides. (1992) (0)
2', 3'-Dideoxynucleoside Analogues : Development of Anti-Viral Therapy for HTLV-III/LAV Associated Diseases (1986) (0)
HIV: Antiviral Chemotherapy (1989) (0)
Abstract B247: Integration of a modularized protein engineering technology and the RheoSwitch Therapeutic System® platform to develop high affinity trastuzumab single chain variable fragment-Fc proteins for gene therapy applications. (2013) (0)
ULMWH (heparin, ultra low molecular weight) for the treatment of asthma (1996) (0)
Treatment of acquired immunodeficiency syndrome. (1990) (0)
Interactions between radioresistant T Cells from plasmacytoma‐bearing mice and radiosensitive T Cells from normal mice leading to suppression (2007) (0)
6 CELL SPECIES-DEPENDENT METABOLISM OF THE POTENT ANTI-HIV (HUMAN IMMUNODEFICIENCY VIRUS) COMPOUNDS 3\[primes]-AZIDO-2\[primes],3\[primes]-DIDEOXYTHYMIDINE AND 2\[primes],3\[primes]-DIDEOXYCYTIDINE (1988) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Samuel E. Broder?

Samuel E. Broder is affiliated with the following schools:

Samuel E. Broder's Academic­Influence.com Rankings

Samuel E. Broder's Degrees

Why Is Samuel E. Broder Influential?

Samuel E. Broder's Published Works

Published Works

What Schools Are Affiliated With Samuel E. Broder?

Samuel E. Broder's AcademicInfluence.com Rankings